The International AIDS Vaccine Initiative is also accompanying this phase 1 process that will be carried out in 56 American adults without the virus.
The mRNA technology raises hope in the midst of this trial due to the success it has had in developing coronavirus vaccines. Photo: Shutterstock.
The start of human trials once morest the vaccine once morest the HIVby the modern pharmaceuticalwhich has biotechnology from messenger RNAwhich is used in its vaccines once morest covid-19.
The implementation of mRNA technology raises hope in the midst of this trial due to the success it has had in developing coronavirus vaccines.
“By using mRNA to develop drugs, we take advantage of normal biological processes to create the desired therapeutic effect. This gives us the potential to treat a wide spectrum of diseases, many of which cannot be addressed with current therapies”, mentions the laboratory on its website.
This would be the first immunological of this type used to combat the Human Immunodeficiency Virus following several decades of research, so it is expected that the volunteers will have a positive response and it will be possible to start implementing it around the world to save the lives of thousands. of people.
The scientists’ goal is to stimulate the immune system so that the body’s B cells produce bnAb antibodies that can act once morest variants of this virus.
“Induction of bnAbs is widely considered to be a target of vaccination once morest HIVand this is the first step in that process,” the Moderna lab said in a press release.
If the response of the volunteers is as expected once morest the virus that causes the sidathe researchers are considering using a booster that allows the vaccine to be further enhanced.
These first experimental doses were applied at the George Washington University (GWU) School of Medicine and Health Sciences in Washington, DC, in collaboration with IAVI, the Bill and Melinda Gates Foundation, and the nonprofit scientific research organization.
“We are very pleased to partner with IAVI and the Bill & Melinda Gates Foundation to apply our mRNA technology in the environment of the HIV. At Moderna, we believe that mRNA offers a unique opportunity to address critical unmet public health needs around the world,” said Stephen Hoge, President of Moderna.
Meanwhile, the health status of the people who received the biological and the response of their immune system in this important medical advance once morest the deadly disease are being evaluated.
consulted source here.